238 related articles for article (PubMed ID: 23207933)
1. The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.
Herfarth H
Dig Dis; 2012; 30 Suppl 2():55-9. PubMed ID: 23207933
[TBL] [Abstract][Full Text] [Related]
2. Will a 5-ASA a day keep the cancer (and dysplasia) away?
Rubin DT; Lashner BA
Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
[TBL] [Abstract][Full Text] [Related]
3. Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: a methodological question.
Margagnoni G; Pagnini C; Menasci F; Festa S; Delle Fave G
Curr Clin Pharmacol; 2014 Feb; 9(1):84-90. PubMed ID: 24218994
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine.
Allgayer H; Kruis W
Clin Gastroenterol Hepatol; 2006 Apr; 4(4):521; author reply 521. PubMed ID: 16616360
[No Abstract] [Full Text] [Related]
5. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
6. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
7. [Colorectal cancer in inflammatory bowel disease].
Henriksen M; Moum B
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2696-9. PubMed ID: 17952155
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of colorectal cancer: feasibility in everyday practice?
Herszényi L; Farinati F; Miheller P; Tulassay Z
Eur J Cancer Prev; 2008 Nov; 17(6):502-14. PubMed ID: 18941372
[TBL] [Abstract][Full Text] [Related]
9. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
10. [Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921656
[No Abstract] [Full Text] [Related]
11. [5-aminosalicylic acid and cancer prophylaxis?].
Thomsen OO
Ugeskr Laeger; 2006 May; 168(21):2047. PubMed ID: 16768920
[No Abstract] [Full Text] [Related]
12. 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
Ikeda I; Tomimoto A; Wada K; Fujisawa T; Fujita K; Yonemitsu K; Nozaki Y; Endo H; Takahashi H; Yoneda M; Inamori M; Kubota K; Saito S; Nagashima Y; Nakagama H; Nakajima A
Clin Cancer Res; 2007 Nov; 13(21):6527-31. PubMed ID: 17975166
[TBL] [Abstract][Full Text] [Related]
13. [Does 5-ASA prevent development of colon cancer in ulcerative colitis?].
Fallingborg JF
Ugeskr Laeger; 2006 May; 168(21):2049-51. PubMed ID: 16768921
[TBL] [Abstract][Full Text] [Related]
14. The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven.
Terdiman JP
Am J Gastroenterol; 2011 Apr; 106(4):737-40. PubMed ID: 21468069
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.
Rubenstein JH; Waljee AK; Jeter JM; Velayos FS; Ladabaum U; Higgins PD
Am J Gastroenterol; 2009 Sep; 104(9):2222-32. PubMed ID: 19491824
[TBL] [Abstract][Full Text] [Related]
16. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
Ullman T; Croog V; Harpaz N; Hossain S; Kornbluth A; Bodian C; Itzkowitz S
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1225-30; quiz 1177. PubMed ID: 18848502
[TBL] [Abstract][Full Text] [Related]
17. The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway.
Munding J; Ziebarth W; Pox CP; Ladigan S; Reiser M; Hüppe D; Brand L; Schmiegel W; Tannapfel A; Reinacher-Schick AC
Carcinogenesis; 2012 Mar; 33(3):637-43. PubMed ID: 22198215
[TBL] [Abstract][Full Text] [Related]
18. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Velayos FS; Terdiman JP; Walsh JM
Am J Gastroenterol; 2005 Jun; 100(6):1345-53. PubMed ID: 15929768
[TBL] [Abstract][Full Text] [Related]
19. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X; Ma J; Wang K; Zhang H
Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
[TBL] [Abstract][Full Text] [Related]
20. The role of aminosalicylates in the treatment of ulcerative colitis.
Van Assche G; Baert F; De Reuck M; De Vos M; De Wit O; Hoang P; Louis E; Mana F; Pelckmans P; Rutgeerts P; Van Gossum A; D'Haens G
Acta Gastroenterol Belg; 2002; 65(4):196-9. PubMed ID: 12619425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
